UNITED THERAPEUTICS CORP

USC CFO Edgemond James’s June 8 trades signal a planned liquidity move, converting options to cash while retaining a strong share stake in United Therapeutics.

CEO Martine Rothblatt’s June 8 buy of $146‑share United Therapeutics stocks signals long‑term confidence, offering investors a potential entry point amid a bullish pipeline and rising valuations.

Insider moves at United Therapeutics: CEO Martina Rothblatt’s bulk buys and sales reveal a disciplined option‑driven strategy, large trust holdings, and a possible short‑term supply spike that could hint at a valuation peak while underscoring long‑t…

Insider Paul Mahon’s disciplined 10 b5‑1 trades show a steady 49,400‑share holding, confirming long‑term confidence in United Therapeutics’ growth and pipeline.

U.S. CEO Martine Rothblatt’s disciplined 10‑b5‑1 plan buying 9,500 UTX shares at $146.03 shows confidence in United Therapeutics’ growth while keeping insider trades predictable and non‑volatility‑creating.

United Therapeutics CEO Martina Rothblatt’s June 2026 insider trades—buy low at $146, sell high around $540 under a 10b‑5(1) plan—show disciplined portfolio rebalancing, not distress, giving investors confidence in UTHR’s stable growth outlook.

Insight: CFO Edgemond James’ May 18 insider option exercise shows strong confidence in United Therapeutics’ 83% YTD rally, suggesting a bullish long‑term stance for investors.

United Therapeutics CEO’s 10‑b‑5‑1 trades show strategic rebalancing and confidence—buy low, sell high—while keeping a long‑term stake for investors.

United Therapeutics insider trades reveal a strategic 10‑b‑5‑1 plan: executives buying low, selling high to fund R&D and acquisitions while signaling long‑term confidence in its prostacyclin pipeline.

Insider buying at United Therapeutics shows executives remain bullish on future growth, even amid modest price swings and a solid pipeline of inhaled therapies.